CordenPharma gives collection of carbohydrate molecules

Partnership with CMO will allow GlycoNet researchers to work with a greater selection of oligosaccharides


By Rebecca Medel

GlycoNet is pleased to announce a collaboration with CordenPharma International on a library of oligosaccharides.

“We are delighted that CordenPharma International will be partnering with GlycoNet by providing a collection of complex oligosaccharides for use in our Glycan Screening Core Service,” said GlycoNet Scientific Director Todd Lowary. “This contribution will substantially enhance our collection by adding a range of mammalian and microbial glycans, which will greatly facilitate the identification of ligands for carbohydrate-binding proteins relevant to the Network’s funded research programs.”

CordenPharma is a Contract Manufacturing Organization that was founded in 2006 with eight facilities throughout the US and Europe. It partners with pharmaceutical and biotechnology companies by equipping them with synthetic carbohydrates, glycolipids and glycopeptides.

“The collaboration with GlycoNet represents an important step in CordenPharma’s goal of becoming the recognized world leader in the manufacture of synthetic complex carbohydrates, including GMP and commercial production,” said Head of Operations US Stewart Campbell. “The brain trust and capabilities encompassed by GlycoNet will only enhance the already world-renowned Canadian carbohydrate research community and CordenPharma is proud to have the opportunity to participate in this worthwhile effort.”

The library of carbohydrates is an important contribution to the work of GlycoNet’s 25 funded research projects. It will include dozens of compounds covering a variety of carbohydrate classes including:

Glycosaminoglycans (GAG) from the heparin/heparan sulfate class ranging from di- to octasaccharides in size and with a variety of defined sulfation patterns.

Mammalian oligosaccharides (non-GAG)  (mono- to nonasaccharides) from the high-mannose class and the milk oligosaccharides class (LNFP-III, LnNT).

Microbe-related oligosaccharides based on known microbial polysaccharides, including Meningococcus B, Group A Streptococcus (hexa- and dodecasaccharides), poly-N-acetyl-glucosamines, Leishmania variable cap regions, and beta-glucans.

Scroll to Top